Vikas Khetan, M.B.B.S.

Dr. Khetan leads the ocular oncology service at Flaum Eye Institute. Ocular oncology encompasses the diagnosis and treatment of tumors that occur in or around the eye. These tumors can range from harmless to potentially life-threatening, and may cause vision loss or loss of the eye itself. Dr Khetan...

Dr. Khetan leads the ocular oncology service at Flaum Eye Institute. Ocular oncology encompasses the diagnosis and treatment of tumors that occur in or around the eye. These tumors can range from harmless to potentially life-threatening, and may cause vision loss or loss of the eye itself. Dr Khetan specializes in treatment of tumors inside the eye (Intraocular tumors).

Dr. Khetan also play vital roles on the retina team, as an adult and pediatric retina surgeon, and within the ocular genetics group of the pediatric service, where he is the primary surgeon performing gene therapy.

Dr. Khetan came to FEI after being in practice for 15 years at Sankara Nethralaya, a tertiary eye care center in Chennai, India. He completed his MBBS and internship at JSS Medical College, Mysore University, Mysore, India, and received his diploma in ophthalmology from Kasturba Medical College, Manipal, India. He completed a fellowship in Vitreoretinal diseases at the Medical Research Foundation, Sankara Nethralaya, India, and then came to North America to continue his training. First he did a fellowship in Ocular Oncology at Toronto’s Hospital for Sick Kids (pediatrics/retinoblastoma) and Princess Margaret Hospital Adult Oncology Clinic (adults). Dr. Khetan then traveled to Wills Eye Hospital in Philadelphia to complete a fellowship in Ocular Genetics. Khetan’s research interests include retinoblastoma and ocular genetics.

Khetan has an impressive record of more than 100 peer-reviewed publications appearing in international journals of ophthalmology. He is a member of the Association for Research in Vision and Ophthalmology where is also a member of the Annual Meeting Program Committee (AMPC- Oncology) from 2021-2024 and is an Executive Member of the Asia Pacific Society of Ocular Oncology and Pathology (APSOOP).